Neridronate treatment in chilfren with osteogenesis imperfecta (OI): the effedts on bone mineral density (BMD) and vertebral deformities by Celli, M. et al.
NERIDRONATE TREATMENT IN CHILDREN WITH OSTEOGENESIS 
IMPERFECTA (OI): THE EFFECTS ON BONE MINERAL DENSITY (BMD) 
AND VERTEBRAL DEFORMITIES
M. Celli1, D. Diacinti2, A. Zambrano1, P. D’Eufemia1, M. Tetti1, R. Del Fiacco2, 
V. Baldini2, E. D’Erasmo2
1 Department of Pediatrics, University of Rome “La Sapienza”, Rome, Italy
2 Department of Clinical Sciences, University of Rome “La Sapienza”, Rome, Italy
To evaluate the effects of neridronate treatment on bone mass and vertebral deformities in children with
OI. 
In 21 children (8 M, 13 F; age 1-12 aa), with OI (types I, III e IV) in therapy with neridronate (2 mg/kg i.v.
every 3 months), were evaluated lumbar bone mass (BMD e BMAD) and vertebral deformities by mor-
phometric X-ray absorptiometry (MXA) using QDR4500A (Hologic). By MXA were calculated the wedging
index [(1-ah/ph)x100%] and concavity index [(1-mh/ph)x100%]. 
A significant increase of BMD was observed after 12 months, from 0.08±0.01 to 0.09±0.01 (+17.1%;
p<0.01); the indexes of vertebral deformity were reduced (wedging: -4.64% n.s.; biconcavity: 
-7.5% n.s.) and inversely correlated to the BMD (r=-0.372) and to the BMAD (r=-0.376).
The semiquantitative (SQ) assessment of the radiographs and the MXA revealed the same number and
grade of vertebral fractures in 13/20 children.
Our data confirm the effectiveness of the therapy with neridronate increasing the bone density; the rela-
tionship between the morphometric indexes and the BMD suggest the possibility to use the MXA (low-
dose method), in the follow-up for the children with IO for the identification of vertebral fractures.
196 Clinical Cases in Mineral and Bone Metabolism 2005; 2(3): 185-252
BSTR CT (V Congresso CCMBM)  18/11/2005  15.59  Pagina 196
FOR
 REV
IEW 
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
